We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
At basic research level, new experimental models are being constructed that may overcome the limitations of animal models: fibroblast cultures, de-differentiation to induced pluripotent stem cells (IPSC), differentiation to dopaminergic neurones, all from the fibroblasts of the patients, being able to study the genetic, epigenetic, and metabolomics profiles.
At clinical science level of diagnostic application: molecular biomarkers in peripheral blood (microRNAs), or in cerebrospinal fluid (the measurement of factors like coenzyme Q10, cytokines, or proteins involved in neurodegeneration like alpha-synuclein itself, beta-amyloid, or tau protein, all with different techniques such as ELISA, multiplex platforms, or aggregometry techniques like RTQuIC ["real time quaking induced conversion"]).
At a clinical investigation level of experimental treatments, apart from clinical trials of new dopaminergic drugs or drugs against dyskinesia or directed at non-motor symptoms, the great focus of interest are clinical trials of molecules that are potential modifiers of the course of the disease. Two examples of these being conservative iron chelation with deferiprone and passive immunisation with anti-alpha-synuclein monoclonal antibodies directed, respectively, at reducing oxidative stress and clearance of the excess synuclein that spreads the intraneuronal aggregates.These trials are pending results.
Discover the projects and active clinical trials on this disease.
Sorry this content wasn't helpful to you. Send us your comment and we will take it into account to continue improving.
Thanks for your help!
An error has occurred and we were unable to send your opinion, please try again later.
Substantiated information by:
Almudena Sánchez Gómez
Ana Cámara Lorenzo
Maria José MartíHead of the Parkinson's and Movement Disorders Unit
Yaroslau Compta Hirnyj
Published: 8 July 2019
Updated: 14 November 2019
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.